Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.
- 1. Altoida Inc., Washington DC, Washington, DC (DC), 20003, USA
- 2. Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics, Ionian University, 7 Tsirigoti Square, Corfu, Greece
Description
Parkinson's disease (PD) is the fastest growing neurodegeneration and has a prediagnostic phase with a lot of challenges to identify clinical and laboratory biomarkers for those in the earliest stages or those 'at risk'. Despite the current research effort, further progress in this field hinges on the more effective application of digital biomarker and artificial intelligence applications at the prediagnostic stages of PD. It is of the highest importance to stratify such prediagnostic subjects that seem to have the most neuroprotective benefit from drugs. However, current initiatives to identify individuals at risk or in the earliest stages that might be candidates for future clinical trials are still challenging due to the limited accuracy and explainability of existing prediagnostic detection and progression prediction solutions. In this brief paper, we report on a novel digital neuro signature (DNS) for prodromal-PD based on selected digital biomarkers previously discovered on preclinical Alzheimer's disease. (AD). Our preliminary results demonstrated a standard DNS signature for both preclinical AD and prodromal PD, containing a ranked selection of features. This novel DNS signature was rapidly repurposed out of 793 digital biomarker features and selected the top 20 digital biomarkers that are predictive and could detect both the biological signature of preclinical AD and the biological mechanism of a-synucleinopathy in prodromal PD. The resulting model can provide physicians with a pool of patients potentially eligible for therapy and comes along with information about the importance of the digital biomarkers that are predictive, based on SHapley Additive exPlanations (SHAP). Similar initiatives could clarify the stage before and around diagnosis, enabling the field to push into unchartered territory at the earliest stages of the disease.
Files
openreseurope-1-15331.pdf
Files
(2.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:17b12c3e368ae0b5c92a1d97b8c10d02
|
2.0 MB | Preview Download |
Additional details
References
- de Lau LM, Breteler MM (2006). Epidemiology of Parkinson's disease. Lancet Neurol. doi:10.1016/S1474-4422(06)70471-9
- de Rijk MC, Tzourio C, Breteler MM (1997). Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp.62.1.10
- Twelves D, Perkins KSM, Counsell C (2003). Systematic review of incidence studies of Parkinson's disease. Mov Disord. doi:10.1002/mds.10305
- Heinzel S, Roeben B, Ben-Shlomo Y (2016). Prodromal markers in Parkinson's disease: limitations in longitudinal studies and lessons learned. Front Aging Neurosci. doi:10.3389/fnagi.2016.00147
- Obeso JA, Stamelou M, Goetz CG (2017). Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. doi:10.1002/mds.27115
- Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015). Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci. doi:10.3389/fncel.2015.00124
- Rees RN, Acharya AP, Schrag A (2018). An early diagnosis is not the same as a timely diagnosis of Parkinson's disease [version 1; peer review: 2 approved]. F1000Res. doi:10.12688/f1000research.14528.1
- Noyce AJ, Lees AJ, Schrag A (2016). The prediagnostic phase of Parkinson's disease. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2015-311890
- Chaudhuri KR, Sauerbier A (2016). Parkinson disease. Unravelling the nonmotor mysteries of Parkinson disease. Nat Rev Neurol. doi:10.1038/nrneurol.2015.236
- Noyce AJ, Bestwick JP, Silveira-Moriyama L (2013). PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2013-305420
- Berg D, Postuma RB, Adler CH (2015). MDS research criteria for prodromal Parkinson's disease. Mov Disord. doi:10.1002/mds.26431
- Schrag A, Horsfall L, Walters K (2015). Prediagnostic presentations of Parkinson's disease in primary care: a case-control study. Lancet Neurol. doi:10.1016/S1474-4422(14)70287-X
- Balestrino R, Hurtado-Gonzalez CA, Stocchi F (2019). Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). NPJ Parkinsons Dis. doi:10.1038/s41531-019-0097-1
- Meier IB, Buegler M, Harms R (2021). Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study. NPJ Digit Med. doi:10.1038/s41746-021-00470-z
- Buegler M, Harms RL, Balasa M (2020). Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimers Dement (Amst). doi:10.1002/dad2.12073
- Ogawa M, Maruo K, Sone D (2019). Longitudinal analysis of risk factors for dementia based on Mild Cognitive Impairment Screen results and questionnaire responses from healthy Japanese individuals registered in an online database. Alzheimers Dement (N Y). doi:10.1016/j.trci.2019.06.003
- Sachdev PS, Brodaty H, Reppermund S (2010). The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int Psychogeriatr. doi:10.1017/S1041610210001067
- Peloso GM, Beiser AS, Satizabal CL (2020). Cardiovascular health, genetic risk, and risk of dementia in the framingham heart study. Neurology. doi:10.1212/WNL.0000000000010306
- Lourida I, Hannon E, Littlejohns TJ (2019). Association of lifestyle and genetic risk with incidence of dementia. JAMA. doi:10.1001/jama.2019.9879
- Solomon A, Kivipelto M, Molinuevo JL (2018). European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open. doi:10.1136/bmjopen-2017-021017
- Rosenberg A, Mangialasche F, Ngandu T (2020). Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS. J Prev Alzheimers Dis. doi:10.14283/jpad.2019.41
- Rossini PM, Cappa SF, Lattanzio F (2019). The Italian INTERCEPTOR Project: From the Early Identification of Patients Eligible for Prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer's Disease Diagnosis. J Alzheimers Dis. doi:10.3233/JAD-190670
- Olazarán J, Valentà M, Frades B (2015). The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer's Disease. Front Aging Neurosci. doi:10.3389/fnagi.2015.00181
- Muurling M, de Boer C, Kozak R (2021). Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimers Res Ther. doi:10.1186/s13195-021-00825-4
- Chen T, Guestrin C (2016). XGBoost: A Scalable Tree Boosting System. In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. doi:10.1145/2939672.2939785
- Lundberg SM, Lee SI (2017). A Unified Approach to Interpreting Model Predictions.
- Lundberg SM, Erion G, Chen H (2020). From Local Explanations to Global Understanding with Explainable AI for Trees. Nat Mach Intell. doi:10.1038/s42256-019-0138-9